Plasma Hydrogen Sulfide as a Biomarker for Alzheimer's Disease and Related Dementias

NCT05060848 | Active Not Recruiting

• 1 other identifier: 00000059
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Hydrogen sulfide is a signaling molecule that is important for vascular health. Because vascular factors such as hypertension and high cholesterol are risk factors for Alzheimer's disease and related dementias, we hypothesize that hydrogen sulfide plays an important role in brain health as well. We will compare blood levels of hydrogen sulfide across groups of people with and without dementia. We will also look at the relationship between hydrogen sulfide, cognitive dysfunction and measures of brain microvascular disease examine the contribution of hydrogen sulfide to cognitive decline. Our goal is to identify a biomarker of vascular dysfunction in dementia.

Conditions

Alzheimer Disease; Dementia

Keywords

biomarker; vascular disease; sex differences; race differences

Outcome Measures

Primary Outcomes (3)

• Cognitive Outcomes

  ADAS Cog score

  Prospective, single measurement

• Imaging Outcomes

  MRI based brain volume measures, FLAIR lesion volume

  Prospective, single measurement

• Blood Outcomes

  Plasma Hydrogen sulfide including metabolites: free, acid labile, bound and total sulfides.

  Prospective, single measurement

Secondary Outcomes (1)

• Demographic Data

  Prospective, single measurement

Other Outcomes (1)

• Comorbidity Data (covariates)

  Prospective, single measurement

Study Arms (2)

ADRD

Participants in the ADRD group will have a score of greater than or equal to 17 on the ADAS-cog, a paper and pencil test of cognitive function including memory. Subgroups based on sex and race categories will also be examined.

Control

Participants in the control group will have a score of less than 17 on the ADAS-cog, a paper and pencil test of cognitive function including memory

Eligibility Criteria

• Age: 55 Years - 100 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

A total of 50 people with a study based diagnosis of AD (ADAS-cog score ≥17) and 50 controls will be enrolled in the study.

You may qualify if:

• All participants must be aged \>55 years with English as the 1⁰ language, with stable permitted medications for \<4 weeks, geriatric depression scale score \<6, visual and auditory acuity adequate to perform tests, and history of education excluding developmental cognitive abnormalities.

Sponsors & Collaborators

• Louisiana State University Health Sciences Center Shreveport: lead

Study Sites (1)

LSU Health Shreveport Center for Brain Health

Shreveport, Louisiana, 71103, United States

Location

Related Publications (1)

• Disbrow E, Stokes KY, Ledbetter C, Patterson J, Kelley R, Pardue S, Reekes T, Larmeu L, Batra V, Yuan S, Cvek U, Trutschl M, Kilgore P, Alexander JS, Kevil CG. Plasma hydrogen sulfide: A biomarker of Alzheimer's disease and related dementias. Alzheimers Dement. 2021 Aug;17(8):1391-1402. doi: 10.1002/alz.12305. Epub 2021 Mar 12.

  PMID: 33710769 RESULT

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood

MeSH Terms

Conditions

Alzheimer Disease; Dementia; Vascular Diseases

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Cardiovascular Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor, Dept. of Neurology

Study Record Dates

• First Submitted: September 20, 2021
• First Posted: September 29, 2021
• Study Start: April 1, 2021
• Primary Completion: May 1, 2026
• Study Completion (Estimated): May 1, 2027
• Last Updated: March 8, 2023

Record last verified: 2023-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)